ClinicalTrials.gg
CompletedNCT00489359Updated Jun 16, 2011Results posted

Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

A Phase 1/2 interventional study of Pemetrexed - Phase 1 and Carboplatin - Phase 1 in Ovarian Cancer and Primary Peritoneal Cancer, sponsored by Eli Lilly and Company. Completed at 22 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-16.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pemetrexed in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Ovarian Neoplasms.

Enrollment
2nd of 12
86 · median 36
Started
2005
with 3 others
Phase 1/2
Only one
of the 13
Registered
7th of 13
by date
Lead sponsor
4 of 13
Eli Lilly and Company

Among the 13 studies testing pemetrexed in Ovarian Neoplasms, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2005, is the only one in phase 1/2, and was the 7th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 13 studies testing pemetrexed in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing pemetrexed in Ovarian Neoplasms as a file.
02

Study summary

The purpose of this study is to determine efficacy of the combination therapy of pemetrexed and carboplatin as treatment for patients with platinum-sensitive ovarian cancer. This study also includes patients with primary peritoneal cancer.

03

Conditions studied

  • Ovarian Cancer
  • Primary Peritoneal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ovarian or primary peritoneal cancer confirmed by pathology
  • Patients must have recurrent ovarian cancer which is sensitive to platinum therapy
  • Prior radiation therapy is allowed

as defined by the (RECIST) guidelines, or non-measurable but cancer antigen 125 (CA-125) greater than or equal to 2X upper limit.

Exclusion criteria

Exclusion Criteria:

  • More than 2 for ovarian or primary peritoneal cancer.
  • Pregnant or breast feeding.
  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Pemetrexed/Carboplatin Phase 1

    Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.

    Drug: Pemetrexed - Phase 1 · Drug: Carboplatin - Phase 1

  • Experimental
    Pemetrexed/Carboplatin Phase 2

    Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.

    Drug: Pemetrexed - Phase 2 · Drug: Carboplatin - Phase 2

Interventions

  • 500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)

    Also known as: LY231514, Alimta

  • DrugCarboplatin - Phase 1

    area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)

  • Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles

    Also known as: LY231514, Alimta

  • DrugCarboplatin - Phase 2

    Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles

06

What researchers measure

Primary outcomes

  1. Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin

    MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 and carboplatin Area Under the Concentration-Time Curve (AUC) up to 6 mg/mL\*min based on observed pattern of dose limiting toxicity (DLT). See Outcome #3 for DLT. If none of 3 initial participants at a given level experienced a DLT in Cycle 1, enrollment proceeded to the next dose level. If at least 2 participants experienced a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from a different Phase 2 Study (NCT00109096), further dose escalations were not explored.

    Time frame: First treatment to toxicity (up to 18 months)

  2. Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)

    Response is defined as CR (Complete Response) or PR (Partial Response) per Response Evaluation Criteria in Solid Tumor (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. Response rate (%) = (number of patients with CR+PR/number of patients in Phase 2)\*100

    Time frame: baseline to measured progressive disease (PD) (up to 18 months)

Secondary outcomes

  1. Phase 1 - Number of Dose-Limiting Toxicities (DLTs)

    The following toxicities were considered DLT: CTCAE Grade 4 neutropenia (absolute neutrophil count \[ANC\] \<0.5 × 10\^9/L lasting ≥7 days. Febrile neutropenia (ANC \<1.0 × 10\^9/L, fever 38.5°C, and no documented infection). CTCAE Grade 4 thrombocytopenia (platelets \<25.0 × 10\^9/L). Any hemorrhage with CTCAE Grade ≥3 thrombocytopenia (50.0 × 10\^9/L). CTCAE Grade ≥3 nonhematologic toxicity (excluding nausea, vomiting, or CTCAE Grade 3 alanine transaminase (ALT) or aspartate aminotransferase (AST) that returned to baseline prior to next treatment). Treatment delay more than 1 week due to toxicity.

    Time frame: baseline through end of Phase 1 (up to 18 months)

  2. Phase 1 - Number of Participants With Adverse Events (Toxicity)

    A listing of adverse events is located in the Reported Adverse Event module.

    Time frame: baseline measured to progressive disease (up to 18 months)

  3. Phase 1 - Recommended Dose of Pemetrexed for Phase 2

    MTD was to be used as Phase 2 recommended dose. MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 based on observed pattern of dose limiting toxicity (DLT: See Outcome #3). If none of 3 initial participants at a given level had a DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from another Phase 2 Study (NCT00109096), further dose escalations were not explored and dose was selected based on results of that Phase 2 Study.

    Time frame: baseline measured to progressive disease (up to 18 months)

  4. Phase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 2

    MTD was to be used as Phase 2 recommended dose. MTD determined by increasing doses up to AUC 6 mg/mL\*min based on pattern of DLT (Outcome #3). If none of 3 initial participants at given level had DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had DLT in Cycle 1 at dose level, that dose level was considered MTD. However, based on results from Phase 2 Study (NCT00109096), further dose escalations were not explored: carboplatin dose was selected based on standard dose employed in control arm of first-line therapy for epithelial ovarian cancer (Bookman 2006).

    Time frame: baseline measured to progressive disease (up to 18 months)

  5. Phase 1 - Number of Participants With Tumor Response

    Patients were analyzed by Cancer Antigen-125 (CA-125) response criteria and RECIST guidelines. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: baseline measured to progressive disease (up to 18 months)

  6. Phase 2 - Time to Response (TTR)

    Response is defined as CR (Complete Response) or PR (Partial Response) per RECIST criteria. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: First treatment to response (up to 31 months)

  7. Phase 2 - Duration of Response (DOR)

    Duration of response is defined as the time from first observation of Complete Response or Partial Response to the first observation of Progressive Disease or death from any cause. For patients who are still alive at the time of analysis, and who do not have Progressive Disease, duration of response will be censored at the date of the last objective progression-free disease assessment.

    Time frame: time of response to progressive disease (up to 31 months)

  8. Phase 2 - Time to Disease Progression

    Time to objective progressive disease (TTPD) is defined as the time from the date of study enrollment to the date of objectively determined Progressive Disease (PD). For patients who die without objective PD (including death from study disease), TTPD will be censored at the date of the last objective progression-free disease assessment. For patients who are still alive at the time of analysis, and who do not have PD, TTPD will be censored at the date of the last objective progression-free disease assessment.

    Time frame: baseline to measured progressive disease (up to 31 months)

  9. Phase 2 - Time to Treatment Failure

    Time to treatment failure (TTTF) is defined as the time from the date of study enrollment to the date of the first observation of disease progression, death from any cause, or early discontinuation of treatment (any reason). For patients who are alive, progression-free, and have not discontinued early at the time of analysis, TTTF will be censored at the date of the last objective progression-free disease assessment.

    Time frame: First treatment to discontinuation of study drug, progressive disease, or death (up to 31 months)

  10. Phase 2 - Overall Survival

    Overall survival is defined as the time from the date of study enrollment to the date of death from any cause. This analysis was not done due to the high number of censored patients.

    Time frame: baseline to date of death from any cause (up to 31 months)

  11. Phase 2 - Number of Participants With Adverse Events (Toxicity)

    A listing of adverse events is located in the Reported Adverse Event module.

    Time frame: baseline through end of Phase 2 (up to 31 months)

  12. Phase 2 - Progression-Free Survival

    Progression-free survival (PFS) is defined as the time from the date of study enrollment to the date of objectively determined PD or death from any cause, whichever comes first. For patients who are still alive at the time of analysis, and who do not have PD, PFS will be censored at the date of the last objective progression-free disease assessment.

    Time frame: baseline to measured progressive disease (up to 31 months)

07

Results

Posted Jun 16, 2011

Participant flow

Participant flow — Overall Study
MilestonePemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2
Started2066
Completed1337
Not completed729
Withdrew: Death02
Withdrew: Progressive disease56
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject15
Withdrew: Adverse event016

Outcome measures

PrimaryPhase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin

MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 and carboplatin Area Under the Concentration-Time Curve (AUC) up to 6 mg/mL\*min based on observed pattern of dose limiting toxicity (DLT). See Outcome #3 for DLT. If none of 3 initial participants at a given level experienced a DLT in Cycle 1, enrollment proceeded to the next dose level. If at least 2 participants experienced a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from a different Phase 2 Study (NCT00109096), further dose escalations were not explored.

Time frame:
First treatment to toxicity (up to 18 months)
Reported as:
Number · mg/m^2

No measurements were reported for this outcome.

PrimaryPhase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)

Response is defined as CR (Complete Response) or PR (Partial Response) per Response Evaluation Criteria in Solid Tumor (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. Response rate (%) = (number of patients with CR+PR/number of patients in Phase 2)\*100

Time frame:
baseline to measured progressive disease (PD) (up to 18 months)
Reported as:
Number · percentage of participants
Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)
percentage of participantsPemetrexed/Carboplatin Phase 2
Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)32.8 (21.3 to 46.0)
SecondaryPhase 1 - Number of Dose-Limiting Toxicities (DLTs)

The following toxicities were considered DLT: CTCAE Grade 4 neutropenia (absolute neutrophil count \[ANC\] \<0.5 × 10\^9/L lasting ≥7 days. Febrile neutropenia (ANC \<1.0 × 10\^9/L, fever 38.5°C, and no documented infection). CTCAE Grade 4 thrombocytopenia (platelets \<25.0 × 10\^9/L). Any hemorrhage with CTCAE Grade ≥3 thrombocytopenia (50.0 × 10\^9/L). CTCAE Grade ≥3 nonhematologic toxicity (excluding nausea, vomiting, or CTCAE Grade 3 alanine transaminase (ALT) or aspartate aminotransferase (AST) that returned to baseline prior to next treatment). Treatment delay more than 1 week due to toxicity.

Time frame:
baseline through end of Phase 1 (up to 18 months)
Reported as:
Number · DLT events
Phase 1 - Number of Dose-Limiting Toxicities (DLTs)
DLT eventsPemetrexed/Carboplatin Phase 1
Number of DLT Events1
DLT Event: Grade 4 Neutropenia1
SecondaryPhase 1 - Number of Participants With Adverse Events (Toxicity)

A listing of adverse events is located in the Reported Adverse Event module.

Time frame:
baseline measured to progressive disease (up to 18 months)
Reported as:
Number · Participants
Phase 1 - Number of Participants With Adverse Events (Toxicity)
ParticipantsPemetrexed/Carboplatin Phase 1
Serious Adverse Events2
Other Adverse Events19
SecondaryPhase 1 - Recommended Dose of Pemetrexed for Phase 2

MTD was to be used as Phase 2 recommended dose. MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 based on observed pattern of dose limiting toxicity (DLT: See Outcome #3). If none of 3 initial participants at a given level had a DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from another Phase 2 Study (NCT00109096), further dose escalations were not explored and dose was selected based on results of that Phase 2 Study.

Time frame:
baseline measured to progressive disease (up to 18 months)
Reported as:
Number · mg/m^2 (milligrams per square meter)
Phase 1 - Recommended Dose of Pemetrexed for Phase 2
mg/m^2 (milligrams per square meter)Pemetrexed/Carboplatin Phase 1
Phase 1 - Recommended Dose of Pemetrexed for Phase 2500
SecondaryPhase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 2

MTD was to be used as Phase 2 recommended dose. MTD determined by increasing doses up to AUC 6 mg/mL\*min based on pattern of DLT (Outcome #3). If none of 3 initial participants at given level had DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had DLT in Cycle 1 at dose level, that dose level was considered MTD. However, based on results from Phase 2 Study (NCT00109096), further dose escalations were not explored: carboplatin dose was selected based on standard dose employed in control arm of first-line therapy for epithelial ovarian cancer (Bookman 2006).

Time frame:
baseline measured to progressive disease (up to 18 months)
Reported as:
Number · mg/mL*min
Phase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 2
mg/mL*minPemetrexed/Carboplatin Phase 1
Phase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 26
SecondaryPhase 1 - Number of Participants With Tumor Response

Patients were analyzed by Cancer Antigen-125 (CA-125) response criteria and RECIST guidelines. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
baseline measured to progressive disease (up to 18 months)
Reported as:
Number · Participants
Phase 1 - Number of Participants With Tumor Response
ParticipantsPemetrexed/Carboplatin Phase 1
Complete Response (CR)12
Partial Response (PR)4
Stable Disease (SD)1
Progressive Disease (PD)2
SecondaryPhase 2 - Time to Response (TTR)

Response is defined as CR (Complete Response) or PR (Partial Response) per RECIST criteria. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
First treatment to response (up to 31 months)
Reported as:
Median · Months
Phase 2 - Time to Response (TTR)
MonthsPemetrexed/Carboplatin Phase 2
Phase 2 - Time to Response (TTR)1.8 (1.4 to 2.8)
SecondaryPhase 2 - Duration of Response (DOR)

Duration of response is defined as the time from first observation of Complete Response or Partial Response to the first observation of Progressive Disease or death from any cause. For patients who are still alive at the time of analysis, and who do not have Progressive Disease, duration of response will be censored at the date of the last objective progression-free disease assessment.

Time frame:
time of response to progressive disease (up to 31 months)
Reported as:
Median · Months
Phase 2 - Duration of Response (DOR)
MonthsPemetrexed/Carboplatin Phase 2
Phase 2 - Duration of Response (DOR)9.1 (6.9 to 10.2)
SecondaryPhase 2 - Time to Disease Progression

Time to objective progressive disease (TTPD) is defined as the time from the date of study enrollment to the date of objectively determined Progressive Disease (PD). For patients who die without objective PD (including death from study disease), TTPD will be censored at the date of the last objective progression-free disease assessment. For patients who are still alive at the time of analysis, and who do not have PD, TTPD will be censored at the date of the last objective progression-free disease assessment.

Time frame:
baseline to measured progressive disease (up to 31 months)
Reported as:
Median · Months
Phase 2 - Time to Disease Progression
MonthsPemetrexed/Carboplatin Phase 2
Phase 2 - Time to Disease Progression9.5 (8.3 to 11.3)
SecondaryPhase 2 - Time to Treatment Failure

Time to treatment failure (TTTF) is defined as the time from the date of study enrollment to the date of the first observation of disease progression, death from any cause, or early discontinuation of treatment (any reason). For patients who are alive, progression-free, and have not discontinued early at the time of analysis, TTTF will be censored at the date of the last objective progression-free disease assessment.

Time frame:
First treatment to discontinuation of study drug, progressive disease, or death (up to 31 months)
Reported as:
Median · Months
Phase 2 - Time to Treatment Failure
MonthsPemetrexed/Carboplatin Phase 2
Phase 2 - Time to Treatment Failure7.1 (4.6 to 8.5)
SecondaryPhase 2 - Overall Survival

Overall survival is defined as the time from the date of study enrollment to the date of death from any cause. This analysis was not done due to the high number of censored patients.

Time frame:
baseline to date of death from any cause (up to 31 months)
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryPhase 2 - Number of Participants With Adverse Events (Toxicity)

A listing of adverse events is located in the Reported Adverse Event module.

Time frame:
baseline through end of Phase 2 (up to 31 months)
Reported as:
Number · participants
Phase 2 - Number of Participants With Adverse Events (Toxicity)
participantsPemetrexed/Carboplatin Phase 2
Serious Adverse Events15
Other Adverse Events63
SecondaryPhase 2 - Progression-Free Survival

Progression-free survival (PFS) is defined as the time from the date of study enrollment to the date of objectively determined PD or death from any cause, whichever comes first. For patients who are still alive at the time of analysis, and who do not have PD, PFS will be censored at the date of the last objective progression-free disease assessment.

Time frame:
baseline to measured progressive disease (up to 31 months)
Reported as:
Median · Months
Phase 2 - Progression-Free Survival
MonthsPemetrexed/Carboplatin Phase 2
Phase 2 - Progression-Free Survival9.4 (8.3 to 11.1)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed 500 + Carboplatin AUC 5 (Phase 1)—1/4 (25%)4/4 (100%)
Pemetrexed 600 + Carboplatin AUC 5 (Phase 1)—0/3 (0%)3/3 (100%)
Pemetrexed 600 + Carboplatin AUC 6 (Phase 1)—0/4 (0%)4/4 (100%)
Pemetrexed 700 + Carboplatin AUC 6 (Phase 1)—0/3 (0%)3/3 (100%)
Pemetrexed 800 + Carboplatin AUC 6 (Phase 1)—1/3 (33.3%)3/3 (100%)
Pemetrexed 900 + Carboplatin AUC 6 (Phase 1)—1/3 (33.3%)2/3 (66.7%)
Pemetrexed 500 + Carboplatin AUC 6 (Phase 2)—15/66 (22.7%)63/66 (95.5%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPemetrexed 500 + Carboplatin AUC 5 (Phase 1)Pemetrexed 600 + Carboplatin AUC 5 (Phase 1)Pemetrexed 600 + Carboplatin AUC 6 (Phase 1)Pemetrexed 700 + Carboplatin AUC 6 (Phase 1)Pemetrexed 800 + Carboplatin AUC 6 (Phase 1)Pemetrexed 900 + Carboplatin AUC 6 (Phase 1)Pemetrexed 500 + Carboplatin AUC 6 (Phase 2)
AnaemiaBlood and lymphatic system disorders0/40/30/40/31/30/33/66
ConstipationGastrointestinal disorders0/40/30/40/30/31/30/66
Gastrointestinal haemorrhageGastrointestinal disorders1/40/30/40/30/30/30/66
Drug hypersensitivityImmune system disorders0/40/30/40/30/30/33/66
VomitingGastrointestinal disorders0/40/30/40/30/30/32/66
DyspnoeaRespiratory, thoracic and mediastinal disorders0/40/30/40/30/30/32/66
PancytopeniaBlood and lymphatic system disorders0/40/30/40/30/30/31/66
ThrombocytopeniaBlood and lymphatic system disorders0/40/30/40/30/30/31/66
TachycardiaCardiac disorders0/40/30/40/30/30/31/66
Abdominal painGastrointestinal disorders0/40/30/40/30/30/31/66
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPemetrexed 500 + Carboplatin AUC 5 (Phase 1)Pemetrexed 600 + Carboplatin AUC 5 (Phase 1)Pemetrexed 600 + Carboplatin AUC 6 (Phase 1)Pemetrexed 700 + Carboplatin AUC 6 (Phase 1)Pemetrexed 800 + Carboplatin AUC 6 (Phase 1)Pemetrexed 900 + Carboplatin AUC 6 (Phase 1)Pemetrexed 500 + Carboplatin AUC 6 (Phase 2)
ThrombocytopeniaBlood and lymphatic system disorders2/41/33/43/32/30/314/66
ConstipationGastrointestinal disorders4/42/32/43/31/32/321/66
NauseaGastrointestinal disorders4/42/33/43/33/32/342/66
VomitingGastrointestinal disorders2/42/34/43/33/31/327/66
FatigueGeneral disorders3/42/34/42/33/31/333/66
HeadacheNervous system disorders2/43/33/41/31/32/35/66
NeutropeniaBlood and lymphatic system disorders0/42/33/41/32/30/332/66
StomatitisGastrointestinal disorders3/40/30/40/32/31/310/66
Back painMusculoskeletal and connective tissue disorders3/40/32/40/31/30/32/66
FlushingVascular disorders1/42/33/40/30/31/36/66

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
Mean56.99 ± 11.0657.71 ± 10.4457.54 ± 10.52
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
Female206686
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
Caucasian205979
Hispanic077
Region of Enrollment
Region of Enrollment(participants)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
Canada077
Argentina01414
Poland055
Germany203151
Sweden099
Performance Status
Performance Status(participants)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
ECOG Status 034649
ECOG Status 1172037
Tumor Type
Tumor Type(participants)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
Ovarian Cancer156176
Peritoneal Cancer5510
Platinum-free interval
Platinum-free interval(participants)Pemetrexed/Carboplatin Phase 1Pemetrexed/Carboplatin Phase 2Total
<6 months033
6-12 months62329
>12 months144054
08

Study locations

22 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bahia Blanca, B8000HXM, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1199ACK, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ramos Mejia, B1704ESN, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salta, 4400, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2N 4N2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M5G 2M9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13353, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bonn, 53127, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chemnitz, D-09116, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Duesseldorf, 40489, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Erlangen, D-91054, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, DE-45145, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 22081, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jena, D-07743, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kiel, D-24105, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55131, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tübingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-402, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olsztyn, 10-228, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 00909, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Göteborg, 416 85, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lund, 22241, Sweden
09

References and documents

Publications

  • Bookman MA. 2006. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24 (suppl 18S). Abstract 5002.
  • Sehouli J, Alvarez AM, Manouchehrpour S, Ghatage P, Szczylik C, Zimmermann A, Bauknecht T, Look KY, Oskay-Oezcelik G. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2012 Feb;124(2):205-9. doi: 10.1016/j.ygyno.2011.09.007. Epub 2011 Nov 1. PubMed 22044606 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2007
First posted
Jun 21, 2007
Start
Jul 2005
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Jun 16, 2011
Last update
Jun 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00489359
First posted
Jun 21, 2007
Start date
Jul 2005
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Jun 16, 2011
Last update
Jun 16, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion